Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-244X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial ; volume:20 ; number:1 ; day:8 ; month:1 ; year:2020 ; pages:1 ; date:12.2020
BMC psychiatry ; 20, Heft 1 (8.1.2020), 1, 12.2020
- Urheber
-
Smith-Apeldoorn, Sanne Y.
Veraart, Jolien K. E.
Kamphuis, Jeanine
Asselt, Antoinette D. I. van
Touw, Daan J.
Rot, Marije aan het
Schoevers, Robert A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12888-019-2398-7
- URN
-
urn:nbn:de:101:1-2020041406041005147178
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Smith-Apeldoorn, Sanne Y.
- Veraart, Jolien K. E.
- Kamphuis, Jeanine
- Asselt, Antoinette D. I. van
- Touw, Daan J.
- Rot, Marije aan het
- Schoevers, Robert A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Personalized use of ketamine and esketamine for treatment-resistant depression
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Treatment-resistant depression: molecular mechanisms and management
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Personalized use of ketamine and esketamine for treatment-resistant depression
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Treatment-resistant depression: molecular mechanisms and management
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Personalized use of ketamine and esketamine for treatment-resistant depression
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Treatment-resistant depression: molecular mechanisms and management
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials